Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.
The prevalence of extensively drug-resistant tuberculosis (XDR-TB), defined as TB that is resistant to isoniazid, rifampin, fluoroquinolones, and aminoglycosides, is rising worldwide. The extent of Mycobacterium tuberculosis resistance to fluoroquinolones depends on the mutation in the DNA gyrase, the only target of fluoroquinolones. The MIC of moxifloxacin, the most active fluoroquinolone against M. tuberculosis, may be lower than its peak serum level for some ofloxacin-resistant strains of Mycobacterium tuberculosis. Therefore, if the MIC of moxifloxacin is lower than its peak serum level, it may be effective against XDR-TB. Our objective was to determine the efficacy of moxifloxacin in treating ofloxacin-resistant TB. We selected isogenic fluoroquinolone-resistant mutants of M. tuberculosis H37Rv in vivo. We infected Swiss mice with either wild-type H37Rv or one of three mutant strains with different MICs that are commonly seen in clinical practice. The MICs of the mutant strains ranged from below to above the peak moxifloxacin level seen in humans (3 μg/ml). Each mouse was treated with one of four moxifloxacin doses for 1 month. Moxifloxacin was effective against mutant strain GyrB D500N, with the lowest MIC (0.5 μg/ml), when the standard dose was doubled. Moxifloxacin reduced mortality in mice infected with mutant strain GyrA A90V with an intermediate MIC (2 μg/ml). However, it had no impact on the mutant strain GyrA D94G with the highest MIC (4 μg/ml). Our study underscores current WHO recommendations to use moxifloxacin when there is resistance to early-generation fluoroquinolones such as ofloxacin, restricting this recommendation to strains with moxifloxacin MICs of less than or equal to 2 μg/ml.
Poissy
Julien
J
Laboratoire de Bactériologie-Hygiène, Faculté de Médecine, Pierre et Marie Curie Université Paris, 91 Boulevard de l'hôpital, Paris Cedex 13, France.
Aubry
Alexandra
A
Fernandez
Christine
C
Lott
Marie-Catherine
MC
Chauffour
Aurelie
A
Jarlier
Vincent
V
Farinotti
Robert
R
Veziris
Nicolas
N
D000818:Animals; D000995:Antitubercular Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001372:Aza Compounds / Q000493:pharmacokinetics / Q000627:therapeutic use*; D027081:DNA Gyrase / Q000235:genetics; D015365:Enoxacin / Q000627:therapeutic use; D024841:Fluoroquinolones / Q000627:therapeutic use; D000077734:Gatifloxacin; D051379:Mice; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D009154:Mutation; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000235:genetics; D015242:Ofloxacin / Q000627:therapeutic use; D011804:Quinolines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014376:Tuberculosis / Q000382:microbiology; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000235:genetics
D000995:Antitubercular Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D015365:Enoxacin; D015242:Ofloxacin; D027081:DNA Gyrase; D000077734:Gatifloxacin; D000077266:Moxifloxacin
Antimicrob Agents Chemother. 2009 Nov;53(11):4835-9
19721073
Antimicrob Agents Chemother. 2007 Feb;51(2):576-82
17145798
Respir Med. 2006 Sep;100(9):1566-72
16469488
Lancet. 2008 Oct 18;372(9647):1403-9
18723218
MMWR Morb Mortal Wkly Rep. 2007 Mar 23;56(11):250-3
17380107
Biochim Biophys Acta. 1998 Oct 1;1400(1-3):29-43
9748489
Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):541-6
15634738
Antimicrob Agents Chemother. 2005 Mar;49(3):1046-54
15728901
Antimicrob Agents Chemother. 1998 Aug;42(8):2066-9
9687408
Infection. 2005 Dec;33 Suppl 2:29-35
16518709
Int J Tuberc Lung Dis. 2008 Feb;12(2):128-38
18230244
Antimicrob Agents Chemother. 2003 Oct;47(10):3117-22
14506018
N Engl J Med. 2001 Jul 19;345(3):170-4
11463011
Lancet. 2006 Nov 4;368(9547):1575-80
17084757
J Antimicrob Chemother. 2003 May;51(5):1109-17
12697644
MMWR Recomm Rep. 2009 Feb 13;58(RR-3):1-43
19214162
Biotechnology. 1992;24:104-8
1422003
Emerg Infect Dis. 2005 Jun;11(6):814-20
15963274
Antimicrob Agents Chemother. 1999 Jan;43(1):85-9
9869570
Eur Respir J. 2006 Nov;28(5):980-5
16837502
Antimicrob Agents Chemother. 2009 Mar;53(3):849-62
19075046
Lancet. 2006 Mar 18;367(9514):938-40
16546542
Antimicrob Agents Chemother. 1999 Jun;43(6):1508-10
10348784
Antimicrob Agents Chemother. 2004 Apr;48(4):1281-8
15047530
Am J Respir Crit Care Med. 2005 Dec 1;172(11):1457-62
16141439
Am J Respir Crit Care Med. 2004 May 15;169(10):1103-9
14742301
Antimicrob Agents Chemother. 1996 Aug;40(8):1768-74
8843279
N Engl J Med. 2008 Aug 7;359(6):563-74
18687637
Nature. 1998 Jun 11;393(6685):537-44
9634230
Antimicrob Agents Chemother. 2000 Oct;44(10):2600-3
10991830
N Engl J Med. 2001 Apr 26;344(17):1294-303
11320389
Wkly Epidemiol Rec. 2006 Nov 10;81(45):430-2
17096498
Eur Respir J. 2009 May;33(5):1085-94
19164345
Lancet. 2009 Apr 4;373(9670):1183-9
19345831
Am J Respir Crit Care Med. 2006 Aug 1;174(3):331-8
16675781
Microb Drug Resist. 2006 Spring;12(1):7-11
16584301
Clin Infect Dis. 2006 Oct 1;43(7):841-7
16941364
J Antimicrob Chemother. 2007 May;59(5):860-5
17412727
J Antimicrob Chemother. 1999 May;43 Suppl B:69-76
10382878
Am J Respir Crit Care Med. 2007 Jan 1;175(1):6-8
17179495
Antimicrob Agents Chemother. 1994 Apr;38(4):773-80
8031045
Antimicrob Agents Chemother. 2006 Jan;50(1):104-12
16377674
MMWR Morb Mortal Wkly Rep. 2006 Mar 24;55(11):301-5
16557213
Am J Respir Crit Care Med. 2009 Aug 1;180(3):273-80
19406981
J Infect Dis. 2006 Aug 15;194(4):479-85
16845631